Prognosis after percutaneous closure of patent foramen ovale for paradoxical embolism
Abstract
The long-term risk and risk factors for recurrent embolism after percutaneous closure of patent foramen ovale (PFO) were investigated in 152 consecutive patients with presumed paradoxical embolism. During follow-up, the actuarial freedom from recurrent embolism was 95.1% at 1 year, and 90.6% at 2 and 6 years. A residual shunt after percutaneous PFO closure was a predictor for recurrence (RR 5.3; 95% CI 1.3 to 21.0; p = 0.02). Randomized trials comparing medical treatment with percutaneous PFO closure in the prevention of recurrent embolism are in progress.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Overall JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology. 2000; 55: 1172–1179.
2.
Bridges ND, Hellenbrand W, Latson L, Filiano J, Newburger JW, Lock JE. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation. 1992; 86: 1902–1908.
3.
Hung J, Landzberg MJ, Jenkins KJ, et al. Closure of patent foramen ovale for paradoxical emboli: intermediate-term. J Am Coll Cardiol. 2000; 35: 1311–1316.
4.
Windecker S, Wahl A, Chatterjee T, et al. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation. 2000; 101: 893–898.
5.
Webster MW, Chancellor AM, Smith HJ, et al. Patent foramen ovale in young stroke patients. Lancet. 1988; 2: 11–12.
6.
Dearani JA, Ugurlu BS, Danielson GK, et al. Surgical patent foramen ovale closure for prevention of paradoxical embolism-related cerebrovascular ischemic events. Circulation. 1999; 100: II171–175.
7.
Mas JL, Zuber M. Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm. Am Heart J. 1995; 130: 1083–1088.
8.
Bogousslavsky J, Garazi S, Jeanrenaud X, Aebischer N, Van Melle G. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group. Neurology. 1996; 46: 1301–1305.
9.
Homma S, Di Tullio MR, Sacco RL, Sciacca RR, Smith C, Mohr JP. Surgical closure of patent foramen ovale in cryptogenic stroke patients. Stroke. 1997; 28: 2376–2381.
10.
Ruchat P, Bogousslavsky J, Hurni M, Fischer AP, Jeanrenaud X, von Segesser LK. Systematic surgical closure of patent foramen ovale in selected patients with cerebrovascular events due to paradoxical embolism. Early results of a preliminary study. Eur J Cardiothorac Surg. 1997; 11: 824–827.
Information & Authors
Information
Published In
Copyright
© 2001.
Publication History
Received: October 5, 2000
Accepted: June 12, 2001
Published online: October 9, 2001
Published in print: October 9, 2001
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Persistence of residual shunt at 6 and 12 months after transoesophageal echocardiography-guided percutaneous closure of a patent foramen ovale for cryptogenic stroke, Heart, 110, 19, (1172-1179), (2024).https://doi.org/10.1136/heartjnl-2024-323905
- Physiotherapy Screening for Referral of a Patient with Patent Foramen Ovale Presenting with Neck Pain as Primary Complaint: A Case Report, Healthcare, 11, 8, (1165), (2023).https://doi.org/10.3390/healthcare11081165
- Paradoxical Embolism Is an Unusual Etiology of Acute Limb Ischemia in Patients Suffering from COVID-19 Infection, Vascular and Endovascular Surgery, 58, 1, (13-19), (2023).https://doi.org/10.1177/15385744231185641
- A Systematic Review and Meta-Analysis of the Association between Residual Shunts after Patent Foramen Ovale Closure and Long-Term Cerebrovascular Events, Cerebrovascular Diseases, 52, 4, (387-392), (2023).https://doi.org/10.1159/000527457
- Désaturation et accident vasculaire cérébral chez une patiente âgée aux urgences : quand le foramen s’en mêle !, Annales françaises de médecine d’urgence, 12, 1, (47-49), (2022).https://doi.org/10.3166/afmu-2022-0374
- Recurrent stroke secondary to late patent foramen ovale-closure device thrombus: a case report, European Heart Journal - Case Reports, 5, 8, (2021).https://doi.org/10.1093/ehjcr/ytab313
- Efficacy and safety of percutaneous patent foramen ovale closure in patients with a hypercoagulable disorder, Catheterization and Cardiovascular Interventions, (2021).https://doi.org/10.1002/ccd.29835
- Percutaneous closure of patent foramen ovale vs. medical treatment for patients with history of cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials, Cardiovascular Revascularization Medicine, 19, 7, (852-858), (2018).https://doi.org/10.1016/j.carrev.2018.02.014
- Meta-analysis of Randomized Controlled Trials on Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Prevention of Cryptogenic Stroke, The American Journal of Cardiology, 121, 11, (1393-1399), (2018).https://doi.org/10.1016/j.amjcard.2018.02.021
- AMPLATZER versus Figulla occluder for transcatheter patent foramen ovale closure, EuroIntervention, 12, 17, (2092-2099), (2017).https://doi.org/10.4244/EIJ-D-15-00499
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.